Decline in the use of anthracyclines for breast cancer

Sharon H. Giordano, Yu Li Lin, Yong Fang Kuo, Gabriel N. Hortobagyi, James Goodwin

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose: To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment. Methods: Claims from a 5% national Medicare sample and from a nationally representative claims database (Marketscan) from 1998 to 2009 were used. Patients with International Classification of Diseases (ICD), ninth revision, codes indicating breast cancer, ICD and Common Procedural Terminology codes indicating breast surgery, and claims for chemotherapy between 3 months before and 12 months after surgery comprised the study cohort. Chemotherapy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated. Piecewise regression models were used to identify the inflection points in the rates of chemotherapy use. The effect of patient characteristics on receiving different types of chemotherapy was estimated by multivariable logistic regression models. Results: A total of 4,458 patients were included in the Medicare cohort and 30,422 in the private insurance cohort. After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline-based chemotherapy was seen. By 2008 in the Medicare cohort, 51% of patients received taxane-based and 32% received anthracycline-based chemotherapy. By the end of 2008, the majority of patients younger than 65 years were also receiving taxane-based chemotherapy. Patients younger than 35 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-gene recurrence score testing and those treated with trastuzumab were more likely to receive taxane-based chemotherapy. Conclusion: The use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy. The potential impact on patient outcomes is unknown.

Original languageEnglish (US)
Pages (from-to)2232-2239
Number of pages8
JournalJournal of Clinical Oncology
Volume30
Issue number18
DOIs
StatePublished - Jun 20 2012

Fingerprint

Anthracyclines
Breast Neoplasms
Drug Therapy
Medicare
International Classification of Diseases
Logistic Models
taxane
Insurance
Terminology
Breast
Cohort Studies
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Decline in the use of anthracyclines for breast cancer. / Giordano, Sharon H.; Lin, Yu Li; Kuo, Yong Fang; Hortobagyi, Gabriel N.; Goodwin, James.

In: Journal of Clinical Oncology, Vol. 30, No. 18, 20.06.2012, p. 2232-2239.

Research output: Contribution to journalArticle

Giordano, Sharon H. ; Lin, Yu Li ; Kuo, Yong Fang ; Hortobagyi, Gabriel N. ; Goodwin, James. / Decline in the use of anthracyclines for breast cancer. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 18. pp. 2232-2239.
@article{c33a708d5cec479eb5b5f65152d43483,
title = "Decline in the use of anthracyclines for breast cancer",
abstract = "Purpose: To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment. Methods: Claims from a 5{\%} national Medicare sample and from a nationally representative claims database (Marketscan) from 1998 to 2009 were used. Patients with International Classification of Diseases (ICD), ninth revision, codes indicating breast cancer, ICD and Common Procedural Terminology codes indicating breast surgery, and claims for chemotherapy between 3 months before and 12 months after surgery comprised the study cohort. Chemotherapy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated. Piecewise regression models were used to identify the inflection points in the rates of chemotherapy use. The effect of patient characteristics on receiving different types of chemotherapy was estimated by multivariable logistic regression models. Results: A total of 4,458 patients were included in the Medicare cohort and 30,422 in the private insurance cohort. After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline-based chemotherapy was seen. By 2008 in the Medicare cohort, 51{\%} of patients received taxane-based and 32{\%} received anthracycline-based chemotherapy. By the end of 2008, the majority of patients younger than 65 years were also receiving taxane-based chemotherapy. Patients younger than 35 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-gene recurrence score testing and those treated with trastuzumab were more likely to receive taxane-based chemotherapy. Conclusion: The use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy. The potential impact on patient outcomes is unknown.",
author = "Giordano, {Sharon H.} and Lin, {Yu Li} and Kuo, {Yong Fang} and Hortobagyi, {Gabriel N.} and James Goodwin",
year = "2012",
month = "6",
day = "20",
doi = "10.1200/JCO.2011.40.1273",
language = "English (US)",
volume = "30",
pages = "2232--2239",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Decline in the use of anthracyclines for breast cancer

AU - Giordano, Sharon H.

AU - Lin, Yu Li

AU - Kuo, Yong Fang

AU - Hortobagyi, Gabriel N.

AU - Goodwin, James

PY - 2012/6/20

Y1 - 2012/6/20

N2 - Purpose: To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment. Methods: Claims from a 5% national Medicare sample and from a nationally representative claims database (Marketscan) from 1998 to 2009 were used. Patients with International Classification of Diseases (ICD), ninth revision, codes indicating breast cancer, ICD and Common Procedural Terminology codes indicating breast surgery, and claims for chemotherapy between 3 months before and 12 months after surgery comprised the study cohort. Chemotherapy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated. Piecewise regression models were used to identify the inflection points in the rates of chemotherapy use. The effect of patient characteristics on receiving different types of chemotherapy was estimated by multivariable logistic regression models. Results: A total of 4,458 patients were included in the Medicare cohort and 30,422 in the private insurance cohort. After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline-based chemotherapy was seen. By 2008 in the Medicare cohort, 51% of patients received taxane-based and 32% received anthracycline-based chemotherapy. By the end of 2008, the majority of patients younger than 65 years were also receiving taxane-based chemotherapy. Patients younger than 35 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-gene recurrence score testing and those treated with trastuzumab were more likely to receive taxane-based chemotherapy. Conclusion: The use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy. The potential impact on patient outcomes is unknown.

AB - Purpose: To determine the patterns of use of anthracycline- and taxane-based chemotherapy for breast cancer treatment. Methods: Claims from a 5% national Medicare sample and from a nationally representative claims database (Marketscan) from 1998 to 2009 were used. Patients with International Classification of Diseases (ICD), ninth revision, codes indicating breast cancer, ICD and Common Procedural Terminology codes indicating breast surgery, and claims for chemotherapy between 3 months before and 12 months after surgery comprised the study cohort. Chemotherapy was classified as anthracycline-based or taxane-based, and the percentages of use were calculated. Piecewise regression models were used to identify the inflection points in the rates of chemotherapy use. The effect of patient characteristics on receiving different types of chemotherapy was estimated by multivariable logistic regression models. Results: A total of 4,458 patients were included in the Medicare cohort and 30,422 in the private insurance cohort. After 2005, a sharp increase in the use of taxane-based chemotherapy and a decline in anthracycline-based chemotherapy was seen. By 2008 in the Medicare cohort, 51% of patients received taxane-based and 32% received anthracycline-based chemotherapy. By the end of 2008, the majority of patients younger than 65 years were also receiving taxane-based chemotherapy. Patients younger than 35 years were less likely to be treated with a taxane-based regimen, whereas patients who underwent 21-gene recurrence score testing and those treated with trastuzumab were more likely to receive taxane-based chemotherapy. Conclusion: The use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy. The potential impact on patient outcomes is unknown.

UR - http://www.scopus.com/inward/record.url?scp=84864000921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864000921&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.40.1273

DO - 10.1200/JCO.2011.40.1273

M3 - Article

C2 - 22614988

AN - SCOPUS:84864000921

VL - 30

SP - 2232

EP - 2239

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -